Publications by authors named "Vanda Bertolli"
Acta Haematol
September 2024
Article Synopsis
- Up to 30% of chronic myeloid leukemia (CML) patients may need a treatment change due to issues with first-line tyrosine kinase inhibitors (TKIs), and bosutinib (BOS) emerges as an effective and safe alternative.
- A study analyzed 132 CML patients treated with BOS across 18 hematology centers, finding that most patients switched due to intolerance to previous TKIs, with a significant number achieving positive treatment outcomes.
- The findings suggest that BOS is a preferred treatment choice, particularly for patients who cannot tolerate previous TKIs, demonstrating its safety and effectiveness in real-life settings.
Article Synopsis
- Aggressive non-Hodgkin lymphoma typically leads to poor long-term survival after chemotherapy relapse, as seen in a patient resistant to standard treatments R-CHOP and R-DHAP.
- The patient achieved remission with the use of pixantrone, followed by high-dose BEAM chemotherapy and autologous stem cell transplantation to consolidate treatment.
- After 20 months post-transplant, the patient remains in continuous complete remission, demonstrating the effectiveness of pixantrone with minimal side effects.
